Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial

OBJECTIVES: To assess the performance of the Geno-Type MTBDRsl v1, a line-probe assay (LPA), to exclude baseline resistance to fluoroquinolones (FQs) and second-line injectables (SLIs) in the Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB 1 (STREAM 1) trial. METHODS:...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Int J Tuberc Lung Dis
Auteurs principaux: Ejo, M., Van Deun, A., Nunn, A., Meredith, S., Ahmed, S., Dalai, D., Tumenbayar, O., Tsogt, B., Dat, P. T., Ha, D. T. M., Hang, P. T., Kokebu, D., Teferi, M., Mebrahtu, T., Ngubane, N., Moodliar, R., Duckworth, L., Conradie, F., Enduwamahoro, E., Keysers, J., De Rijk, P., Mulders, W., Diro, E., Rigouts, L., de Jong, B. C., Torrea, G.
Format: Artigo
Langue:Inglês
Publié: 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614701/
https://ncbi.nlm.nih.gov/pubmed/34615581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5588/ijtld.21.0212
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires